 NEW YORK, March 31, 2021 GLOBE NEWSWIRE -- Anavex Life Sciences Corp. Anavex or the Company Nasdaq: AVXL, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system CNS diseases, today announced that the Independent Data Safety Monitoring Board DSMB for the Companys Phase 2b3 Alzheimers disease study of its investigational compound ANAVEX2-73 blarcamesine has completed its recent pre-planned review of the preliminary Phase 2b3 study data. 